Skip to main content
. 2015 Jun 8;6(27):23582–23593. doi: 10.18632/oncotarget.4361

Figure 2.

Figure 2

A., C. UCA1 expression levels assessed in patients treated with EGFR-TKI-sensitive NSCLC (baseline group) and patients who were without T790M and with T790M mutations. B., D. PFS in patients with acquired resistant patients who were without T790M mutations and with T790M mutations.